What happens when an industry as heavily regulated and historically slow-moving as pharma is forced to accelerate digital transformation? In today’s episode, I welcome Florian Schnappauf, Vice President of Enterprise Commercial Strategy at Veeva Systems, to discuss how Chief Digital Officers (CDOs) are reshaping the pharmaceutical landscape and why their role is now more critical than ever.

The pharmaceutical sector faces mounting pressure to innovate faster, manage costs, and compete with digital-first biotechs. Research predicts the industry will spend $4.5 billion on digital transformation by 2030, a shift that has led to the emergence of CDOs in the pharma C-suite. But what does this role actually entail, and how does it help companies navigate the complexities of drug development, clinical trials, and commercialization?

Florian shares insights on how CDOs are not just supporting digital initiatives but actively orchestrating, building, and operating them. From managing the sheer volume of data generated by clinical trials to ensuring that digital tools enhance—not hinder—the drug development process, the CDO is now a key differentiator between industry leaders and laggards. We also explore how effective digital leadership can shorten timeframes from drug discovery to patient treatment, improve communication with healthcare providers, and ultimately ensure that pharma companies achieve more with fewer resources.

With regulatory hurdles, technological advancements, and shifting market dynamics, the pharmaceutical industry is at a pivotal moment. So, what does the future hold for digital leaders in pharma? How will CDOs continue to evolve, and what lessons can other industries learn from their journey?

Join us as we break down the digital transformation of pharma and the leadership required to drive meaningful change. And as always, I’d love to hear your thoughts—do you think pharma is adapting quickly enough, or is there still a long way to go?

Check out the What Pharma Needs Next podcast.